Titre : Cellules HepG2

Cellules HepG2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Spatial Regression

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment identifier les cellules HepG2 en laboratoire ?

Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine.
Carcinome hépatocellulaire Lignées cellulaires
#2

Quelles techniques sont utilisées pour étudier les HepG2 ?

Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire.
Culture cellulaire Microscopie

Symptômes 2

#1

Les cellules HepG2 présentent-elles des symptômes ?

Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro.
Symptômes Cellules in vitro
#2

Quels marqueurs sont associés aux cellules HepG2 ?

Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques.
Marqueurs tumoraux Enzymes hépatiques

Prévention 2

#1

Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?

Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques.
Prévention des maladies Composés bioactifs
#2

Comment les HepG2 contribuent-elles à la recherche préventive ?

Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique.
Recherche préventive Toxines

Traitements 2

#1

Peut-on utiliser HepG2 pour tester des médicaments ?

Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments.
Essais cliniques Toxicité
#2

Comment les HepG2 aident-elles à développer des traitements ?

Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques.
Développement de médicaments Mécanismes d'action

Complications 2

#1

Quelles complications peuvent être étudiées avec HepG2 ?

Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées.
Cirrhose Cancer du foie
#2

Les HepG2 aident-elles à comprendre les complications du foie ?

Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques.
Mécanismes pathologiques Complications hépatiques

Facteurs de risque 2

#1

Quels facteurs de risque sont étudiés avec HepG2 ?

Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés.
Facteurs de risque Toxines
#2

Comment HepG2 aide à identifier des facteurs de risque ?

Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques.
Évaluation des risques Agents toxiques
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules HepG2 : Questions médicales les plus fréquentes", "headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-11", "dateModified": "2025-05-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules HepG2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hépatocytes", "url": "https://questionsmedicales.fr/mesh/D022781", "about": { "@type": "MedicalCondition", "name": "Hépatocytes", "code": { "@type": "MedicalCode", "code": "D022781", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.436.348" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules HepG2", "alternateName": "Hep G2 Cells", "code": { "@type": "MedicalCode", "code": "D056945", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wilson de Melo Cruvinel", "url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com." } }, { "@type": "Person", "name": "Paulo Luiz Carvalho Francescantonio", "url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil." } }, { "@type": "Person", "name": "Alessandra Dellavance", "url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance", "affiliation": { "@type": "Organization", "name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil." } }, { "@type": "Person", "name": "Luis Eduardo Coelho Andrade", "url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade", "affiliation": { "@type": "Organization", "name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br." } }, { "@type": "Person", "name": "Antônio Carlos Ximenes", "url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes", "affiliation": { "@type": "Organization", "name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A unified Gaussian copula methodology for spatial regression analysis.", "datePublished": "2022-09-23", "url": "https://questionsmedicales.fr/article/36151389", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-20171-1" } }, { "@type": "ScholarlyArticle", "name": "Unveiling the spatial divide in open defecation practices across India: an application of spatial regression and Fairlie decomposition model.", "datePublished": "2023-07-05", "url": "https://questionsmedicales.fr/article/37407050", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2023-072507" } }, { "@type": "ScholarlyArticle", "name": "Modeling spatial determinants of initiation of breastfeeding in Ethiopia: A geographically weighted regression analysis.", "datePublished": "2022-09-15", "url": "https://questionsmedicales.fr/article/36107834", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0273793" } }, { "@type": "ScholarlyArticle", "name": "Measuring spatial inequalities in maternal and child mortalities in Pakistan: evidence from geographically weighted regression.", "datePublished": "2024-08-16", "url": "https://questionsmedicales.fr/article/39152373", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-024-19682-5" } }, { "@type": "ScholarlyArticle", "name": "Elucidating the spatial determinants of heavy metals pollution in different agricultural soils using geographically weighted regression.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36087662", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.scitotenv.2022.158628" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules épithéliales", "item": "https://questionsmedicales.fr/mesh/D004847" }, { "@type": "ListItem", "position": 4, "name": "Hépatocytes", "item": "https://questionsmedicales.fr/mesh/D022781" }, { "@type": "ListItem", "position": 5, "name": "Cellules HepG2", "item": "https://questionsmedicales.fr/mesh/D056945" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules HepG2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules HepG2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules HepG2", "description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Spatial+Regression#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules HepG2", "description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Spatial+Regression#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules HepG2", "description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Spatial+Regression#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules HepG2", "description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Spatial+Regression#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules HepG2", "description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Spatial+Regression#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules HepG2", "description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Spatial+Regression#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules HepG2 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées pour étudier les HepG2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire." } }, { "@type": "Question", "name": "Les cellules HepG2 présentent-elles des symptômes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux cellules HepG2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques." } }, { "@type": "Question", "name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques." } }, { "@type": "Question", "name": "Comment les HepG2 contribuent-elles à la recherche préventive ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique." } }, { "@type": "Question", "name": "Peut-on utiliser HepG2 pour tester des médicaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments." } }, { "@type": "Question", "name": "Comment les HepG2 aident-elles à développer des traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques." } }, { "@type": "Question", "name": "Quelles complications peuvent être étudiées avec HepG2 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées." } }, { "@type": "Question", "name": "Les HepG2 aident-elles à comprendre les complications du foie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont étudiés avec HepG2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés." } }, { "@type": "Question", "name": "Comment HepG2 aide à identifier des facteurs de risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 06/05/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Wilson de Melo Cruvinel

5 publications dans cette catégorie

Affiliations :
  • School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com.

Paulo Luiz Carvalho Francescantonio

5 publications dans cette catégorie

Affiliations :
  • School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil.

Alessandra Dellavance

4 publications dans cette catégorie

Affiliations :
  • Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.

Luis Eduardo Coelho Andrade

4 publications dans cette catégorie

Affiliations :
  • Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
  • Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil. luis.andrade@unifesp.br.

Antônio Carlos Ximenes

3 publications dans cette catégorie

Affiliations :
  • Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil.
Publications dans "Cellules HepG2" :

Cristóvão Luis Pitangueira Mangueira

3 publications dans cette catégorie

Affiliations :
  • Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :

Eloísa Bonfá

3 publications dans cette catégorie

Affiliations :
  • Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :

Fabiano de Almeida Brito

3 publications dans cette catégorie

Affiliations :
  • Department of Clinical Pathology, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
  • Hermes Pardini Group, Vespasiano, MG, Brazil.
Publications dans "Cellules HepG2" :

Sandra Gofinet Pasoto

3 publications dans cette catégorie

Affiliations :
  • Serviço de Reumatologia e Laboratório de Autoimunidade da Divisão de Laboratório Central do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :

Carlos Alberto von Mühlen

3 publications dans cette catégorie

Affiliations :
  • Sociedade Brasileira de Autoimunidade, Porto Alegre, RS, Brazil.

Tao Chen

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Xiaoju Wang

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Lijun Zhou

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Shiling Feng

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Ming Yuan

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Chunbang Ding

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Wei Li

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: liv880213@foxmail.com.
Publications dans "Cellules HepG2" :

Xi Xie

2 publications dans cette catégorie

Affiliations :
  • Hainan Provincial Key Laboratory for Tropical Hydrobiology and Biotechnology, School of Marine Science, Hainan University, Haikou 570228, China. Electronic address: xiexi@hainu.edu.cn.
Publications dans "Cellules HepG2" :

Tiantian Wu

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: 1532892231@qq.com.
Publications dans "Cellules HepG2" :

Lijie Luo

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: luolijie4567@163.com.
Publications dans "Cellules HepG2" :

Sources (10000 au total)

Unveiling the spatial divide in open defecation practices across India: an application of spatial regression and Fairlie decomposition model.

The study contextualises the spatial heterogeneity and associated drivers of open defecation (OD) in India.... The present study involved a secondary cross-sectional survey data from the fifth round of the National Family Health Survey conducted during 2019-2021 in India. We mapped the spatial heterogeneity of... The study was conducted in India and included 636 699 sampled households within 36 states and union territories covering 707 districts of India.... The outcome measure was the prevalence of OD.... The prevalence of OD was almost 20%, with hot spots primarily located in the north-central belts of the country. The rural-urban (26% vs 6%), illiterate-higher educated (32% vs 4%) and poor-rich (52% ... The practice of OD is concentrated in the north-central belt of India and is particularly among the poor, illiterate and socially backward groups. Policy measures should be taken to improve sanitation...

Modeling spatial determinants of initiation of breastfeeding in Ethiopia: A geographically weighted regression analysis.

The World Health Organization (WHO) encourages breastfeeding to begin within the first hour after birth in order to save children's lives. In Ethiopia, different studies are done on the prevalence and... A cross-sectional study was undertaken using the nationally representative 2016 Ethiopian Demographic and Health Survey (EDHS) dataset. Global Moran's I statistic was used to measure whether delayed b... A total weighted sample of 4169 children of aged 0 to 23 months was included in this study. Delayed initiation of breastfeeding was spatially varies across the country with a global Moran's I value of... In Ethiopia initiation of breastfeeding varies geographically across region. A significant hotspot was identified in the Amhara, Afar, and Tigray regions. The GWR analysis revealed that orthodox relig...

Measuring spatial inequalities in maternal and child mortalities in Pakistan: evidence from geographically weighted regression.

In developing countries, the death probability of a child and mother is more significant than in developed countries; these inequalities in health outcomes are unfair. The present study encompasses a ... This study used micro-level household datasets from multiple indicator cluster surveys (MICS) to estimate the DMI. To find out how different the DMI scores were, the inequality ratio and slope were us... The inequality ratio for DMI showed that the upper decile districts are 16 times more prone to mortalities than districts in the lower decile, and the districts of Baluchistan depicted extreme spatial... The findings reveal a significant disparity in DMI and spatial relationships among all mortalities in Pakistan's districts. Additionally, socioeconomic, environmental, health, and housing variables ha...

Spatially clustered patterns of suicide mortality rates in South Korea: a geographically weighted regression analysis.

Suicide mortality remains a global health concern, and community characteristics affect regional variations in suicide. This study investigated spatially clustered patterns of suicide mortality rates ... Suicide mortality rates were estimated by sex, age group, and district, using the 2021 Cause of Death Statistics in South Korea from the MicroData Integrated Service. Community-determinant data for 20... Suicide mortality rates were significantly higher among men (40.64 per 100,000) and adults over the age of 65 years (43.18 per 100,000). The male suicide mortality rates exhibited strong spatial depen... Community cultural and structural factors exacerbate regional disparities in suicide among men. The influencing factors exhibit differential effects and significance depending on the community, highli...

A retrospective investigation of spatial clusters and determinants of diabetes prevalence: scan statistics and geographically weighted regression modeling approaches.

Diabetes and its complications represent a significant public health burden in the United States. Some communities have disproportionately high risks of the disease. Identification of these disparitie... Behavioral Risk Factor Surveillance System data for 2013 and 2016 were provided by the Florida Department of Health. Tests for equality of proportions were used to identify counties with significant c... There was a small but significant increase in the prevalence of diabetes in Florida (10.1% in 2013 to 10.4% in 2016), and statistically significant increases in prevalence occurred in 61% (41/67) of c... The persistent geographic disparities of diabetes prevalence and temporal increases identified in this study are concerning. There is evidence that the impacts of the determinants on diabetes risk var...